Beverly Lyn‐Cook Data-verified

Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.

High Impact

Researcher

Last publication 2025 Last refreshed 2026-05-16

faculty

30 h-index 130 pubs 3,106 cited

Biography and Research Information

OverviewAI-generated summary

Beverly Lyn‐Cook's research focuses on understanding the complex interactions between environmental exposures, human health, and biological systems. Her work investigates sex-based differences in the immunotoxicity of nanoparticles, such as silver and titanium dioxide, and their effects on cellular processes, including histone modifications and DNA methylation.

Further research by Lyn‐Cook and her collaborators examines the metabolome of breast tissues, exploring correlations between microbial dysbiosis and metabolic pathways, particularly in the context of triple-negative breast tumors and disparities between racial groups. She also employs data mining and systematic analysis of large databases, such as the FDA Adverse Events Reporting System (FAERS), to identify and understand drug-related adverse events, with a specific focus on prescription opioids and their cardiovascular risks.

Metrics

  • h-index: 30
  • Publications: 130
  • Citations: 3,106

Selected Publications

  • Abstract C054: Pharmacogenomics evaluation of histone deacetylase inhibitors on the treatment of triple-negative breast cancer subtypes (2025)
  • AI-powered topic modeling: comparing LDA and BERTopic in analyzing opioid-related cardiovascular risks in women (2025)
    32 citations DOI OpenAlex
  • Exposure to a Titanium Dioxide Product Alters DNA Methylation in Human Cells (2024)
    2 citations DOI OpenAlex
  • Identifying Vulnerabilities to NSAID Adverse Events in the U.S. Population: An Analysis of Preexisting Conditions and Sex (2024)
  • Abstract 4253: High expression of specific gene profiles in organoids from African American pancreatic cancer tumors (2024)
  • Investigation of sex-based differences in the immunotoxicity of silver nanoparticles (2024)
    10 citations DOI OpenAlex
  • RxNorm for drug name normalization: a case study of prescription opioids in the FDA adverse events reporting system (2024)
    8 citations DOI OpenAlex
  • A systematic analysis and data mining of opioid-related adverse events submitted to the FAERS database (2023)
    7 citations DOI OpenAlex
  • Identifying Vulnerabilities to NSAID Adverse Events in the US Population: An Analysis of Pre-Existing Conditions and Sex (2023)
  • Epigenotoxicity of Titanium Dioxide Nanoparticles (2023)
    2 citations DOI OpenAlex
  • Abstract 6251: High expression level of GSK3β in basal triple negative breast cancer: Effects of the HDAC inhibitor, vorinostat (2023)
  • Characterization of the Metabolome of Breast Tissues from Non-Hispanic Black and Non-Hispanic White Women Reveals Correlations between Microbial Dysbiosis and Enhanced Lipid Metabolism Pathways in Triple-Negative Breast Tumors (2022)
    11 citations DOI OpenAlex
  • Effect of titanium dioxide nanoparticles on histone modifications and histone modifying enzymes expression in human cell lines (2022)
    8 citations DOI OpenAlex
  • Abstract 1631: Anti-cancer effects of vorinostat on 3D cultured pancreatic cancer cells (2022)
    1 citation DOI OpenAlex
  • Text Fingerprinting and Topic Mining in the Prescription Opioid Use Literature (2021)
    3 citations DOI OpenAlex

View all publications on OpenAlex →

Collaboration Network

42 Collaborators 9 Institutions 3 Countries

Top Collaborators

View profile →
View profile →
View profile →
View profile →

Similar Researchers

Based on overlapping research topics